Relapsing Remitting Multiple Sclerosis: Clinical Trials

10 trials for Relapsing Remitting Multiple Sclerosis, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

10 completed. 10 Phase 4.

By phase and status

PhaseTrialsStatus
Phase 410Completed 10

Follow Relapsing Remitting Multiple Sclerosis: new trials by email Literature Review of Relapsing Remitting Multiple Sclerosis trials Research Report on Relapsing Remitting Multiple Sclerosis

Trials (filtered) newest first · largest first

All 10 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Evaluate Safety/Tolerability in Portuguese Participants With RRMS Transitioning From Current Therapy
peginterferon beta-1a, interferon beta-1a, interferon beta-1b - Relapsing Remitting Multiple Sclerosis
Phase 4CompletedBiogen802017-01-302020-11-25
Fingolimod Effect on Cytokine and Chemokine Levels
Fingolimod 0.5 mg - Relapsing Remitting Multiple Sclerosis
Phase 4CompletedNovartis Pharmaceuticals1262015-03-312019-09-30
Phase IIIB-IV Long-Term Follow-up Study for Patients Who Participated in CAMMS03409
alemtuzumab GZ402673 - Relapsing Remitting Multiple Sclerosis
Phase 4CompletedGenzyme, a Sanofi Company10622015-01-072022-03-28
Evaluation of Patient Retention of Fingolimod vs. Currently Approved Disease Modifying Therapy in Patients With Relapsing Remitting Multiple Sclerosis.
Fingolimod, Disease Modifying therapy - Relapsing Remitting Multiple Sclerosis
Phase 4CompletedNovartis Pharmaceuticals8812012-06-082021-01-05
Evaluation of Patient Reported Outcomes in RRMS Patients Candidates for MS Therapy Change and Transitioned to Fingolimod 0.5 mg (EPOC)
Fingolimod, Interferon beta - 1a (IFN), Glatiramer acetate (GA) - Relapsing Remitting Multiple Sclerosis
Phase 4CompletedNovartis Pharmaceuticals2982012-01-012014-08-08
Efficacy of Fingolimod in de Novo Patients Versus Fingolimod in Patients Previously Treated With a First Line Disease Modifying Therapy
Fingolimod (FTY720) - Relapsing Remitting Multiple Sclerosis
Phase 4CompletedNovartis Pharmaceuticals3472011-12-242019-01-25
Patients With Relapse Remitting Multiple Sclerosis (RRMS): Candidates for MS Therapy Change
Fingolimod, Standard MS DMT - Relapsing Remitting Multiple Sclerosis
Phase 4CompletedNovartis Pharmaceuticals612011-05-012015-06-22
Impact of Vitamin A Supplementation on Immune System in Multiple Sclerosis Patients
Vitamin A, Placebo - Relapsing Remitting Multiple Sclerosis
Phase 4CompletedTehran University of Medical Sciences362009-10-012014-03-14
Study To Evaluate The Immunogenicity And Safety Of r-hIFN Beta-1a (Rebif®) Using Clone 484-39 In Multiple Sclerosis
Rebif® (clone 484-39) - Relapsing Remitting Multiple Sclerosis
Phase 4CompletedMerck KGaA, Darmstadt, Germany4602004-05-012014-02-27
Does Quality of Life Improve in Multiple Sclerosis Patients Treated With Interferon Beta-1a?
Interferon beta-1a - Relapsing Remitting Multiple Sclerosis
Phase 4CompletedBiogen2841999-11-012007-12-13

Narrower conditions

Multiple Sclerosis, Relapsing-Remitting (10)  ·  Multiple Sclerosis (4)

Broader conditions

Autoimmune Diseases (10)  ·  Autoimmune Diseases of the Nervous System (10)  ·  Demyelinating Autoimmune Diseases, CNS (10)  ·  Demyelinating Diseases (10)  ·  Immune System Diseases (10)  ·  Nervous System Diseases (10)  ·  Multiple Sclerosis (6)

Interventions

Fingolimod Hydrochloride (5)  ·  Interferon beta-1a (5)  ·  Glatiramer Acetate (2)  ·  Interferon beta-1b (2)  ·  Vitamin A (1)  ·  peginterferon beta-1a (1)  ·  retinol palmitate (1)

Sponsors

Novartis Pharmaceuticals (5)  ·  Biogen (2)  ·  Genzyme, a Sanofi Company (1)  ·  Merck KGaA, Darmstadt, Germany (1)  ·  Tehran University of Medical Sciences (1)

Countries

Australia (2)  ·  Belgium (2)  ·  Italy (2)  ·  Russia (2)  ·  Spain (2)  ·  United Kingdom (2)  ·  United States (2)  ·  Argentina (1)  ·  Brazil (1)  ·  Canada (1)  ·  Czechia (1)  ·  Denmark (1)  ·  Germany (1)  ·  Iran (1)  ·  Israel (1)

Top investigators

Ali Akbar Saboor Yaraghi, PhD (1)  ·  Bettina Stubinski, M.D. (1)  ·  Renato Turrini, MD (1)  ·  Sima Jafarirad, PhD student (1)

Results publications

PMID 23868508, PMID 31654272, PMID 31762387, PMID 32583052, PMID 32710396, PMID 33476880, PMID 34378446, PMID 34882037, PMID 37745914, PMID 39935588

NIH funding

2016 (1)